BSX Stock Analysis: Buy, Sell, or Hold?
BSX - Boston Scientific Corp.
$63.59
-5.59 (-8.07%)
▼
5d:
-8.56%
30d:
-17.26%
90d:
-33.81%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Apr 22, 2026
22d
Smart Money Accumulation
BSX is down 3.5% this week, but smart money is accumulating calls. Top strike: $90 2026-04-17 with 33,576 OI. Call ratio: 78% View Scanner →
Strength: 4.6/10
Get Alerted When BSX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BSX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: BSX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$137.35
Based on 8.4% avg growth
INTRINSIC VALUE TODAY
$85.29
25.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 23.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BSX is currently trading at $63.59, which is considered oversold relative to its 30-day fair value range of $69.42 to $74.91. From a valuation perspective, the stock is trading at a discount (Forward PE: 17.7) compared to its historical average (23.5). Remarkably, the market is currently pricing in an annual earnings decline of 9.0% over the next few years. This pessimistic expectation contrasts with the company's recent 18.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BSX is in a strong downtrend. The price is currently testing key support at $68.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $102.00 (+47.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BSX is in a strong downtrend. The price is currently testing key support at $68.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $102.00 (+47.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$69.42 -
$74.91
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding BSX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.1%)
- BULLISH: Trading 47.5% below Wall St target ($102.00)
- CAUTION: Recommendation downgraded due to -8.6% 5-day decline
Fair Price Analysis
30-Day Fair Range
$69.42 -
$74.91
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$68.03
Resistance Level
$71.94
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.68
Wall Street Target
$102.00
(+47.5%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
18.5%
Profit Margin
14.4%
Valuation Discount vs History
-9.0% cheaper
PE vs Historical
17.7 vs 23.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.0%
(market-implied from PE analysis)
1-Year Target
$62.94
(-9%)
2-Year Target
$57.28
(-17%)
3-Year Target
$52.12
(-25%)
3-Yr Target (if PE normalizes)
(PE: 18→24)
$69.30
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 12.8%)
$125.92
(+82%)
Base:
(SPY PE: 17.7, Growth: 12.8%)
$99.37
(+44%)
Bear:
(PE: 15.0, Growth: 12.8%)
$84.46
(+22%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 35.81 | Current EPS (TTM): $1.94
Bull Case
$152.86
(+120%)
Analyst growth 100.0%, PE expands to 39.4
Base Case
$138.96
(+100%)
Market implied 100.0%, PE stable at 35.8
Bear Case
$47.25
(-32%)
Severe decline -20.0%, PE contracts to 30.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.7 to 23.5
Stabilization Target:
$91.96
(+32.9%)
PE Expansion Potential:
+32.9%
Share & Embed Analysis
Last updated: March 30, 2026 10:04 AM ET
Data refreshes hourly during market hours. Next update: 11:04 AM
Data refreshes hourly during market hours. Next update: 11:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BSX showing a specific setup today?
Insider Activity (6 Months)
7
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-02-24
Ro Khanna
BUY
2026-02-17
Gilbert Ray Cisneros, Jr.
BUY
2026-02-10
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 48 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 56 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 58 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 56 HOLD |
Advanced BSX Option Strategies
Professional options setups generated by AI based on today's BSX price and gamma walls.
